China / Drugs approved by the Chinese NMPA in 2021
Writing in the May edition of DIA’s Global Forum magazine, Xu Wang of Novo Nordisk China looks at the new drug approvals in China in 2021. Among other highlights, the…
Address: No.97,Lane 1518,Guangfulin Road,Songjiang District,Shanghai,201620,P.R.China
Tel: 86 2161 026 752
Web: http://www.hoborchem.com/
Shanghai Hobor Chemical Co., Ltd is a production-oriented enterprise dedicated to pharmaceutical intermediates and active pharmaceutical ingredients synthesis and process development,Hobor Chemical has been committed to expedite our customer’s R&D and manufacturing in a time and cost effective manner since 2010 the company started.We focuses on developing efficient process technology for intermediates,active ingredients.
Our R&D lab located in Hi-Tech Park of Shanghai,China,the facility located in Fengxin industrial area,Jiangxi Province,employees experienced chemistry and medicine R&D team and equipped with the state of the art instruments.to be able to complete the low temperature of -80 to 300 high temperature a variety of reactions.Our products are strictly controlled by the LC, NMR,MS ensure customer satisfaction with every batch of products. We have established very good relationship with many global customers since company started.
Custom Synthesis As a innovative research company and active high-tech building block supplier, we are eager to become your professional partner in the following fields:
1. Heterocyclic chemistry and it’s synthetic technology
2. APi’s structure and it’s process research3. Cost effective process for pharma intermediates4. Chiral chemicals realted to above region
We provide Explore new synthetic chemistry Synthesis of novel and/or know compounds Substantial experience in process development, scale up and commercialization Able to follow an entire project, from laboratory to pilot production
QA manager is always involved in working together with our marketing colleage to identify suitable supplier, ensure the quality of products, and control the risks in supply chain.
Writing in the May edition of DIA’s Global Forum magazine, Xu Wang of Novo Nordisk China looks at the new drug approvals in China in 2021. Among other highlights, the…
Writing in the April edition of DIA’s Global Forum magazine, the DIA China Leadership and Career Community look at the Chinese pharmaceutical innovation ecosystem’s R&D talent gap and the China Pharmaceutical R&D…
As China struggles to maintain its ‘dynamic zero-COVID’ policy in the face of Omicron variant outbreaks, other key talking points emerging from the world’s second-largest healthcare and life sciences market…
Bridge Consulting’s Zoe Leung examines the journeys of Chinese-developed COVID-19 vaccines outside of China’s borders, drawing on a number of examples, from Sinopharm’s work on boosting vaccine supply in the…
Despite rapidly developing and rolling out two vaccines against COVID-19 – from domestic firms Sinopharm and Sinovac – China is yet to approve a vaccine that uses mRNA technology, either…
The latest news from Chinese healthcare and pharma including Western pharmacos’ moves to license therapies from Chinese partners to sell globally, the seismic impact of new COVID lockdown restrictions in…
Writing in the March 2022 edition of DIA’s Global Forum magazine, Jessie Zhu of Deltamed Co. Ltd./Pharmaron Clinical and Monica Juping Xu of Taimei Medical Technology outline the progress of…
Having consolidated its position as Asia’s largest biotech fundraising hub – and the world’s second largest – the Hong Kong Stock Exchange (HKEX) listed a total of 34 biotech and…
A selection of recent top stories from the Chinese pharma industry, including China’s conditional approval of Pfizer’s COVID treatment pill Paxlovid; a new push to combat monopoly practices and unfair…
PPC China’s Sophia Duan, writing in the January edition of DIA’s Global Forum magazine, details how the emergence of an effective pharmacovigilance ecosystem is helping to safeguard the rollout of…
Some of the biggest stories across China’s healthcare and life science industry today, including the 61.7 percent average price reduction Big Pharma took to get their drugs listed on China’s…
The latest news from Chinese pharma, including an examination of the new national reimbursement drug list (NRDL), the therapies that have and have not made it onto the list, and…
See our Cookie Privacy Policy Here